How would you manage a patient intolerant to oral bisphosphonates?

• A. Increase the dose of oral bisphosphonates
• B. Switch to intravenous zoledronic acid or denosumab; ensure dosing and monitoring; address GI symptoms if present
• C. Discontinue all osteoporosis therapy
• D. Switch to vitamin E supplementation

Answer: (B)

When a patient cannot tolerate oral bisphosphonates, the aim is to continue antiresorptive therapy in a form that is tolerable and effective. Intravenous zoledronic acid delivers the same antiresorptive effect without the GI side effects, usually given as an annual infusion, making it a practical option for GI intolerance. Denosumab offers another effective approach; it’s a subcutaneous injection given every six months and does not rely on the GI tract for absorption, which can be advantageous for those who struggle with oral meds or adherence. In either case, careful dosing and monitoring are important, and it’s essential to check and correct calcium and vitamin D levels before starting, with ongoing consideration of renal function for zoledronic acid and hypocalcemia risk with denosumab.

If GI intolerance is the issue, simply increasing the dose of the oral medication would more likely worsen symptoms. Stopping osteoporosis therapy altogether would raise fracture risk. Vitamin E supplementation doesn’t address the underlying antiresorptive needs of osteoporosis.